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Abstract
Background: Microarray technology is increasingly used to identify potential biomarkers for
cancer prognostics and diagnostics. Previously, we have developed the iterative Bayesian Model
Averaging (BMA) algorithm for use in classification. Here, we extend the iterative BMA algorithm
for application to survival analysis on high-dimensional microarray data. The main goal in applying
survival analysis to microarray data is to determine a highly predictive model of patients' time to
event (such as death, relapse, or metastasis) using a small number of selected genes. Our
multivariate procedure combines the effectiveness of multiple contending models by calculating the
weighted average of their posterior probability distributions. Our results demonstrate that our
iterative BMA algorithm for survival analysis achieves high prediction accuracy while consistently
selecting a small and cost-effective number of predictor genes.
Results: We applied the iterative BMA algorithm to two cancer datasets: breast cancer and diffuse
large B-cell lymphoma (DLBCL) data. On the breast cancer data, the algorithm selected a total of
15 predictor genes across 84 contending models from the training data. The maximum likelihood
estimates of the selected genes and the posterior probabilities of the selected models from the
training data were used to divide patients in the test (or validation) dataset into high- and low-risk
categories. Using the genes and models determined from the training data, we assigned patients
from the test data into highly distinct risk groups (as indicated by a p-value of 7.26e-05 from the
log-rank test). Moreover, we achieved comparable results using only the 5 top selected genes with
100% posterior probabilities. On the DLBCL data, our iterative BMA procedure selected a total of
25 genes across 3 contending models from the training data. Once again, we assigned the patients
in the validation set to significantly distinct risk groups (p-value = 0.00139).
Conclusion: The strength of the iterative BMA algorithm for survival analysis lies in its ability to
account for model uncertainty. The results from this study demonstrate that our procedure selects
a small number of genes while eclipsing other methods in predictive performance, making it a highly
accurate and cost-effective prognostic tool in the clinical setting.
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Background
Introduction and Previous Work
Until recently, oncologists relied primarily on tumor stage
and morphology to help outline an appropriate course of
treatment for their cancer patients. Malignant tumors
were generally resected in operable cases, and follow-up
radiation therapy was provided to victims exhibiting
advanced-stage diseases. This methodology proved prob-
lematic in that a number of low-risk patients experienced
cancer recurrence or death within a short time frame,
while a contingent of high-risk patients went into perma-
nent remission despite the bleak nature of their original
prognoses. This indicated a need to explore other indica-
tors by which doctors could understand the underlying
prognosis of a given disease and decide on a treatment
plan that would optimize the patient's chances for sur-
vival.
Microarray technology provides a promising avenue. The
availability of thousands of gene expression levels has
enabled the pursuit of a new direction in cancer research.
In particular, gene expression patterns can be thought of
as multidimensional quantitative "expression pheno-
types" which can in turn be correlated with clinical out-
come. Because a single microarray can measure the
expression levels of tens of thousands of genes simultane-
ously, the challenge lies in the development of data min-
ing methods and tools to extract biological meaning from
this immense amount of data. More specifically, the aim
is to filter the expression dataset down to the smallest pos-
sible subset of accurate predictor genes. Reducing the
number of predictor genes both decreases clinical costs
and mitigates the possibility of overfitting due to high
inter-variable correlations [1].
The most common approach to identify a manageable
group of predictor genes is called feature selection, in
which a subset of relevant "features" (or variables) is
selected from the full dataset in order to produce a robust
learning model [2,3]. A well-designed feature selection
algorithm will choose a small set of variables that is highly
predictive of clinical outcome. Univariate feature selec-
tion methods evaluate the usefulness of each variable on
an individual basis. Examples of univariate techniques
include the t-test [4], the signal-to-noise ratio [5], the Cox
proportional hazards model [6], threshold number of
misclassification (TNoM) score [7], the between-groups
to within-groups sum of squares (BSS/WSS) ratio [8], and
mean aggregate relevance [9]. Multivariate methods are
more sophisticated in that they perform combinatorial
searches within the feature subspace to evaluate the effec-
tiveness of groups of genes. Examples include Recursive
Feature Elimination (RFE) [10], genetic algorithms [11-
13], floating search [14], and top-scoring pair methods
[15,16]. Despite some evidence to the contrary (e.g.,
[17]), multivariate selection algorithms are generally pref-
erable to univariate ones because they cut down on
dependencies between variables and often lead to models
with fewer predictive variables [18,19]. However, select-
ing multivariate features from microarray data is non-triv-
ial since the number of patient samples is often limited
(usually under a hundred) and the number of genes is
large (usually tens of thousands).
Subsequent to or concurrent with the feature selection
process, a supervised machine learning technique can be
applied to generate a predictive function using the
selected variables from a set of training data [20,21]. In a
supervised learning algorithm, the input is a set of training
samples paired with the corresponding labels of those
samples. If the labels are exhaustive discrete classes to
which the samples belong (e.g. "survived beyond five
years" and "died before five years"), then the learning
model is a classifier (for a review of classification tech-
niques in supervised machine learning, see [22]). With
microarray data, the most common approach is to apply
a classification algorithm in which the patients are split
into subcategories corresponding to different prognoses
or diagnoses. In general, the subcategories are static and
based on thresholds associated with some clinical variable
(e.g., time to metastases). Classification studies on micro-
array data have used gene expression levels to distinguish
diseased tissue samples from normal ones [23,24], iden-
tify cancer subtypes [5,25], and assign discrete risk groups
for survival prognosis [13,19,26-28]. See Hu et al. [29] for
a comparative analysis of classification methods for
microarray data. Depending on whether the classifier is
used to select relevant features, feature selection methods
can also be divided into filter and wrapper methods [30].
Wrapper methods utilize the classifiers as evaluation func-
tions and search for the optimal gene set for classification.
In contrast, filter methods rely on general characteristics
of the training data to select genes without involving any
classifier for evaluation. Many filter methods evaluate a
gene based on its discriminative power for the target
classes without considering its correlations with other
genes. Wrapper algorithms can perform better than filter
algorithms, but they typically require orders of magnitude
more computation time.
In cancer research, gene expression data is often reported
in tandem with time to event information (such as time to
metastasis, death, or relapse). In order to take advantage
of these continuous clinical variables under a supervised
framework, survival analysis can be applied. Survival anal-
ysis on microarray data differs from classification in that
the sample labels are continuous rather than discrete. The
overall goal in survival analysis research is to create the
strongest predictive model of patient survival, and the
most important components of this process are featureBMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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selection and model construction. In the context of sur-
vival analysis, a model  refers to a set of selected genes
whose regression coefficients have been calculated for use
in predicting survival prognosis [31]. In the application of
survival analysis to high-dimensional microarray data, a
feature selection algorithm identifies this subset of genes
from the gene expression training dataset. These genes are
then used to build a statistical model for the continuous
time to event data [32]. The choice of feature selection
algorithm determines which genes are chosen and the
number of predictor genes deemed to be relevant, whereas
the statistical model gives the distribution of the time to
the event.
In recent years, a number of studies have applied survival
analysis to microarray data. Beer et al. [33] used univariate
Cox proportional hazards regression along with leave-
one-out cross validation on an 86-sample lung cancer
dataset to develop a risk index based on 50 genes that suc-
cessfully divided an independent test set of patients into
high- and low-risk groups. Lu et al. [34] improved on
these results by using multivariate Cox proportional haz-
ards model with bootstrap resampling and forward selec-
tion to obtain a 64-gene model that yielded a greater
predictive accuracy than Beer et al. A popular approach to
deal with high dimensionality in survival analysis is
dimension reduction. For example, Bair and Tibshirani
[35] proposed a semi-supervised version of principal
components analysis that is capable of generating a con-
tinuous predictor of patient survival. Their algorithm con-
sistently selected fewer than 20 genes and successfully
divided patients into high- and low-risk groups in four
different cancer subtypes: lymphoma, breast cancer, lung
cancer, and acute myeloid leukemia. Partial least squares
(PLS) reduces the dimension of the original variables by
constructing a smaller collection of latent variables that
are linear combinations of the original variables. The
application of PLS in conjunction with the Cox propor-
tional hazards model in survival analysis to microarray
data has been investigated [36,37]. A drawback of dimen-
sion reduction techniques is that usually a relatively large
number of genes (variables) are selected in the reduced
dimension space. Penalized methods such as LASSO
(least absolute shrinkage and selection operator) [38,39]
is a variable selection method, and hence is an alternative
to dimension reduction techniques as it can be used when
the number of samples is smaller than the number of var-
iables (genes). Zhang et al. [40] studied the theoretical
properties of an adaptive LASSO method for the Cox pro-
portional hazards model. Kaderali et al. [41] proposed a
multivariate Cox regression model embedded in a Baye-
sian framework that combines dimension reduction and
regression in one single step. They used a hierarchical
prior distribution that is strongly peaked around zero on
the regression parameters so as to produce a small
number of relevant genes with non-zero regression
parameters. A distinctive characteristic in Kaderali et al. is
that they assume that the constant baseline hazard rate in
the Cox proportional hazards model is known, and aim to
directly predict survival times of patients. Recently, Bovel-
stad et al. [42] compared the prediction performance of
seven methods that are based on the Cox proportional
hazards model over three microarray datasets, and
showed that ridge regression has the overall best perform-
ance. In their empirical studies, Bovelstad et al. focused on
prediction accuracy instead of the number of selected
genes.
The accelerated failure time (AFT) model [43] is a linear
regression model in which the response variable is the log-
arithm or a known monotone transformation of event
times. Unlike the Cox proportional hazards model which
assumes that the ratio of the hazard functions does not
depend on time and the baseline hazard is unspecified,
one can directly predict event times using the AFT model
and hence, is a useful alternative to the Cox model. How-
ever, the AFT model has not been widely used in practice
due to difficulties in computing the regression parameters
even when the number of variables is small. Recently,
Huang and colleagues [44,45] studied the use of penal-
ized methods in the AFT model for survival analysis. How-
ever, these proposed methods were not applied to
microarray datasets in which thousands or tens of thou-
sands of variables are available. Datta et al. [46] investi-
gated the performances of LASSO and PLS on microarray
data using the AFT model. They showed that LASSO per-
formed better than PLS when there are many noise varia-
bles in their simulation studies.
Our Contributions
A problem with most feature selection algorithms used to
produce continuous predictors of patient survival is that
they fail to account for model uncertainty. With thou-
sands of genes and only tens to hundreds of samples, it
often happens that a number of different models describe
the data about equally well. In this paper, we apply the
Bayesian Model Averaging (BMA) method [47,48] to
select a subset of genes for survival analysis on microarray
data. Instead of choosing a single model and proceeding
as if the data were actually generated from it, BMA com-
bines the effectiveness of multiple models by taking the
weighted average of their posterior distributions. In addi-
tion, BMA consistently identifies a small number of pre-
dictive genes [19,31], and the posterior probabilities of
the selected genes and models are available to facilitate an
easily interpretable summary of the output. Yeung et al.
[19] extended the BMA algorithm to classify high-dimen-
sional microarray; they dealt with the very large number
of potential predictors using an iterative approach. Here
we further extend their iterative BMA method to survivalBMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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analysis. In particular, we developed and implemented
the iterative BMA method for survival analysis as a Bio-
conductor package, and we also demonstrated our algo-
rithm on two cancer datasets. Our results reveal that
iterative BMA consistently selects a small number of pre-
dictor genes while providing greater predictive accuracy
than other algorithms, and the models themselves are
simple and amenable to biological interpretation.
Methods
Data
Breast Cancer
The first dataset in this study consists of patient samples
from primary invasive breast carcinomas [27,49]. The
breast cancer dataset from van't Veer et al. was comprised
of 78 training samples and 19 test samples. Previously
van't Veer et al. identified a 70-gene predictive signature
which classified patient samples into good versus poor
prognosis groups. Subsequently, van de Vijver et al. [49]
acquired a test set of 295 patient samples with clinical
data on which to validate the 70-gene predictive signature.
Of these 295 patient samples, 61 samples overlapped with
the 78 training samples from van't Veer et al. Since differ-
ent clinical data and survival information were made
available from these two publications, we used these 61
overlapping samples as our training set and the remaining
234 samples as our test set, both of which are available on
our supplemental website http://expression.washing
ton.edu/publications/kayee/ibmasurv/. The samples in
both breast cancer datasets were hybridized to two-color
microarrays containing approximately 25,000 genes. Pre-
viously, Yeung et al. [19] filtered the van't Veer et al. data-
set down to 4919 significantly regulated genes (at least a
2-fold difference and p-value < 0.01 in at least three sam-
ples), and we have chosen to conduct our analysis with
these 4919 genes. Of the 295 total samples in our training
and validation datasets, the times to death or censoring
ranged from 0.05 to 18.3 years, with a median of 7.2
years. 216 patients (73%) were still alive at the final fol-
low-up visit. See Table 1 for a summary of the breast can-
cer data.
Lymphoma
Our second dataset consists of tumor samples from 240
patients diagnosed with diffuse large B-Cell lymphoma
(DLBCL) [50]. Roughly 60% of DLBCL victims who are
treated with chemotherapy do not survive, and the disease
comprises 30–40% of all non-Hodgkin lymphomas
[51,52]. This DLBCL dataset was generated and first ana-
lyzed by Rosenwald et al. [50], and the expression profiles
from 7399 genes along with corresponding patient infor-
mation can be downloaded from their supplemental web-
site http://llmpp.nih.gov/DLBCL/. The raw data were
processed with "lymphochip" cDNA microarrays [53],
which are specialized to include genes that are known to
be preferentially expressed within the germinal centers of
lymphoid organs. Survival times ranged from 0 to 21.8
years, with a median of 2.8 years across all samples. Of the
240 patients, only 102 (42.5%) were still alive at the final
follow-up visit. Rosenwald et al. randomly divided the
dataset into 160 training samples and 80 validation sam-
ples, and we have chosen to preserve their division in
order to allow a direct comparison of results. See Table 1
for a summary of the breast cancer and DLBCL datasets.
Bayesian Model Averaging (BMA)
The strength of BMA lies in its ability to account for model
uncertainty, an aspect of analysis that is largely ignored by
traditional stepwise selection procedures [47]. These tra-
ditional methods tend to overestimate the goodness-of-fit
between model and data, and the model is subsequently
unable to retain its predictive power when applied to
independent datasets [31,54]. BMA attempts to solve this
problem by selecting a subset of all possible models and
making statistical inferences using a weighted average of
these models' posterior distributions.
The core of the BMA algorithm is depicted in Equation (1)
below [47]. Let Ψ denote the quantity of interest, and let
S  = {M1,  M2, ..., Mn} represent the subset of models
selected for inclusion in the analysis. Then the posterior
probability of Ψ given the training data TD is the weighted
average of the posterior probability of Ψ given TD and
model  Mi, multiplied by the posterior probability of
model Mi given TD. Summing over all the models in set S,
we get:
There are three issues to consider before Equation (1) can
be applied: obtaining the subset S  of models to be
included, estimating the value of Pr(Ψ | TD, Mi), and esti-
mating the value of Pr(Mi | TD). The remainder of this
subsection will address these issues.
Pr( | ) Pr( | , ) Pr( | ). ΨΨ TD TD M M TD ii
iS
=⋅
∈ ∑ (1)
Table 1: Summary of Breast Cancer and DLBCL Datasets
Dataset Total Number of Samples # Training Samples # Validation Samples Number of Genes
Breast Cancer 295 61 234 4919
DLBCL 240 160 80 7399BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
Page 5 of 17
(page number not for citation purposes)
One challenge with BMA is the sheer number of models
that could potentially be explored by the algorithm, espe-
cially when dealing with microarray data. If there are G
candidate explanatory genes in the expression set, then
there are 2G possible models to consider. When working
with tens of thousands of genes, such an undertaking is
computationally intractable. In order to discard the non-
contributory models and obtain a subset that approxi-
mates an average over all 2G possibilities, Raftery [47]
proposed to use the regression by leaps and bounds algo-
rithm from Furnival and Wilson [55]. This algorithm
takes a user-specified input "nbest" and efficiently returns
the top nbest models of each size (maximum 30 varia-
bles). Following application of the leaps and bounds algo-
rithm, the Occam's window method of Madigan and
Raftery [56] can be used to reduce the set of models. After
identifying the strongest model returned by the leaps and
bounds algorithm, the procedure can eliminate any
model whose posterior probability is below the cutoff
point in relation to the best model. The cutoff point can
be varied, but the default is 20; that is, a model must be at
least 1/20 as likely as the strongest model in order to be
retained. Once this step is complete, the remaining group
of models constitutes the set S to be used in Equation (1).
An exact calculation of the predictive distribution Pr(Ψ |
TD, Mi) requires an integration over the vector of regres-
sion parameters θi:
Pr(Ψ | TD, Mi) = ∫ Pr(Ψ | θi, TD, Mi) Pr(θi | TD, Mi) dθi.
(2)
Because this integral has no closed form solution for most
censored survival models, the maximum likelihood esti-
mate (MLE) can be used as an approximation:
While certain techniques such as the Markov Chain Monte
Carlo (MCMC) methods have been used in survival anal-
ysis to obtain a more exact predictive distribution [57],
the MLE requires fewer computational resources and has
been deemed sufficient for the purpose of averaging over
contending models [31,58-60].
Finally, a calculation of the posterior probability of model
Mi given the training data TD involves an integral whose
value is impossible to evaluate exactly. Bayes' theorem
yields Equation (4), which represents the posterior prob-
ability of model Mi given TD:
Pr(Mi | TD) ∝ Pr(TD | Mi) Pr(Mi), (4)
where
Pr(TD | Mi) = ∫ Pr(TD | θi, Mi) Pr(θi | Mi) dθi.( 5 )
Pr(TD | Mi) is the integrated likelihood of model Mi, and
θi is the vector of regression parameters (b0, b1, ..., bp) of
model Mi. The Bayesian Information Criterion (BIC) first
derived by Schwarz (1978) can be used to approximate
the integral in equation (5):
In equation (6), n represents the number of records in the
data, ki is the number of regression parameters in model
Mi, and O(1) is the error term. The approximation is more
accurate for many practical purposes than its O(1) error
term suggests for certain reasonable choices of the prior
distribution Pr(θi | Mi) [47,61]. Raftery [62] gave further
empirical evidence for the accuracy of this approximation.
This method is implemented in the bic.surv function that
is part of the BMA R package available at http://cran.r-
project.org/web/packages/BMA/index.html
While this section has focused on the posterior probabili-
ties of the models included in the BMA analysis, we are
also interested in obtaining the posterior probabilities for
each of the individual variables (genes) involved. This
information is helpful in facilitating biological discussion
as it reveals which of the genes are relevant predictors. Let
the expression (bi ≠ 0) indicate that the regression param-
eter for gene xi exists in the vector of regression parameters
θi. Then the posterior probability that gene xi is a relevant
predictor can be written as:
The posterior probability of gene xi is the sum of the pos-
terior probabilities of all models in the subset S  that
include gene xi.
BMA for Survival Analysis
Volinsky et al. [31] applied the Bayesian Model Averaging
methods [47,48] to survival analysis. They assessed a
patient's risk of stroke by using BMA to select variables in
Cox Proportional Hazards models [6]. The data were
made available by the Cardiovascular Health Study and
included 23 variables (e.g., age, smoking history, and
blood pressure) that may contribute to a patient's chances
of experiencing a stroke. BMA selected a total of 5 models
and 11 predictive variables, including diuretic, aspirin
use, diabetes, stenosis, and timed walk. Patient risk scores
were calculated by taking the weighted average of the risk
scores for each of the top five contending models. The
patients were then assigned to either the high-risk,
Pr( | , ) Pr( | , , ). ΨΨ TD M TD M ii i ≈ q (3)
logPr( | ) logPr( | , ) ( / )log ( ). TD M TD M k n O ii i i =− + q 21
(6)
Pr( | ) Pr( | ). bM iS M where gene is relevant S
≠= ∑ 0 TD TD
(7)BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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medium-risk, or low-risk group based on the empirical
33rd and 66th percentile cutoff points in the risk scores of
the training set. To assess performance, Volinsky et al. [31]
created an analogue to the log-score called the partial pre-
dictive score (PPS). The PPS for BMA was compared
against the PPS for the top BMA model (that is, the single
model of the top five BMA models with the highest poste-
rior probability) and against the PPS of the model
returned by stepwise backward elimination. BMA exhib-
ited the highest PPS, with a prediction mechanism 15%
more effective than the top model alone and 3.5% more
effective than the stepwise procedure. Furthermore, the
patients assigned to a risk group using BMA experienced
fewer strokes in the low-risk group and more strokes in
the high-risk group when compared with the other two
methods.
Extending BMA for High-Dimensional Microarray Data
Iterative BMA for Classification
The BMA implementation described above is incompati-
ble with microarray data. This is because the typical
microarray dataset contains thousands or even tens of
thousands of genes, but the leaps and bounds algorithm
from Furnival and Wilson [55] tends to become slow
when there are more than 45 variables or so. One com-
mon solution is to use stepwise backward elimination to
reduce the number of genes down to 30, but this is not
applicable in a situation where the number of predictive
variables is greater than the number of samples. Yeung et
al. [19] developed an iterative BMA algorithm that takes a
rank-ordered list of genes and successively applies the tra-
ditional BMA algorithm until all genes up to a user-speci-
fied value p  (G1, G2, ..., Gp) have been processed. The
authors begin by using the ratio of between-group to
within-group sum of squares (BSS/WSS) [8] to rank-order
the genes from the microarray dataset. As the algorithm
iterates, genes with a high posterior probability (equation
(7)) are retained while genes with a low posterior proba-
bility are eliminated. The default threshold for inclusion
is set to 1%; genes whose posterior probabilities are less
than 1% are discarded.
Iterative BMA for Survival Analysis
In this article, we report our efforts in extending the itera-
tive BMA method to survival analysis, which include a
number of modifications to the algorithm. First, instead
of applying the BSS/WSS technique [8] to rank-order the
genes in the preprocessing step, we use the Cox Propor-
tional Hazards Model [6] to rank each individual gene.
Cox regression is a popular choice in the realm of survival
analysis due to its broad applicability and capacity for
handling censored data. It is a semi-parametric method
that quantifies the hazard rate for a subject s at time T as
follows:
λ(T | ps) = λ0(T)exp(psθ). (8)
In this equation, λ0(T) is the baseline hazard function at
time T, ps is the vector of effect parameters (predictors) for
subject s, and θ is the vector of unknown predictor coeffi-
cients. Cox observed that the baseline hazard function in
equation (8) could be left unspecified if the effect of a cov-
ariate on one individual remains the same for all times T
(e.g., if an environmental variable doubles your personal
risk of dying at time 5, it also doubles your risk at time 8).
Therefore, an estimation of θ is all that is needed. This
approximation can be calculated using the partial likeli-
hood:
In equation (9), Rs is the risk set at time ts (where the risk
set consists of individuals who have not yet experienced
the event of interest), and δi is an indicator for whether
subject i is censored. Once the regression parameters in
the Cox model are estimated by maximizing the partial
likelihood, the genes can be ranked in descending order of
their log likelihood.
Following this step, the algorithm iterates through the
user-specified p top-ranked genes, applying the traditional
BMA algorithm for survival analysis [31] to each group of
variables in the current BMA window (where the window
size is denoted by maxNvar). This part of the procedure is
similar to the classification method described previously;
genes with high posterior probabilities are retained while
genes with low posterior probabilities are eliminated. Fol-
lowing Yeung et al. [19], we have chosen to adopt the 1%
default threshold for inclusion. The algorithm relies on
the elimination of at least one gene per iteration from the
current BMA window, so the method cannot proceed if all
genes in the window have a posterior probability ≥ 1%.
Yeung et al. proposed an "adaptive threshold" heuristic to
account for this possibility, whereby the genes with the
lowest posterior probabilities are removed to make room
for subsequent variables. We have incorporated this heu-
ristic into our algorithm because Yeung et al. [19] reported
that its inclusion boosts predictive accuracy. See Figure 1
for an outline of the iterative BMA algorithm for survival
analysis.
Furthermore, we have incorporated an additional heuris-
tic in which the models that are discarded due to the adap-
tive threshold are re-considered when all the iterations are
completed. Specifically, we applied the Occam's window
method of Madigan and Raftery [56] to reduce the set of
models remaining from the last iteration of bic.surv and
PL( )
exp( )
exp( )
. q
q
q
d
=
∈ ∑
⎛
⎝
⎜
⎜
⎞
⎠
⎟
⎟
= ∏
ps
p Rs s
n i
A A 1
(9)BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
Page 7 of 17
(page number not for citation purposes)
the models that are discarded due to the adaptive thresh-
old. We also re-computed the posterior probabilities of
the models and the genes accordingly. In our software
implementation, this heuristic is available as an option
called "keepRmModels" and this option is set to FALSE by
default.
Assessment
To evaluate the performance of our method, we discretize
the risk scores of patients into risk groups. The overall risk
score for a single patient is the weighted average of the risk
scores calculated for each model Mi in the set S of con-
tending models. The equation is as follows [31]:
In equation (10),   represents the vector of regression
parameters for model Mi and   refers to the expression
score of each gene xj within model Mi for a patient in the
validation dataset. Therefore, the risk score is computed
by multiplying the expression scores of all genes included
in model Mi by their corresponding predictor coefficients,
adding these xjbj terms together, weighing this number by
the posterior probability of each model Mi and summing
over all contending models in the set S. Note that the pre-
dictor coefficients and the model posterior probabilities
are all determined from the training data. Our implemen-
tation employs uses the user-specified "cutPoint" for defin-
ing high- versus low-risk groups (e.g., a cutPoint  of 60
means the lower 60% of scores will be deemed low-risk,
and the upper 40% will comprise the high-risk group)
using the risk scores of patients in the training data.
The Kaplan-Meier survival curves [63], in which the pro-
portions of surviving patients in each risk group are plot-
ted against successive time intervals, are used to illustrate
our results. An advantage of the Kaplan-Meier curve is that
it takes censored data into consideration: small vertical
tick-marks represent losses where patient data were cen-
sored. In addition, we measured predictive performance
with the p-value calculated from the log-rank test using
the central chi-square distribution. The log-rank test calcu-
lates a p-value testing the null hypothesis that the survival
curves from the high- and low-risk groups are identical.
Therefore, a significant p-value indicates that the two risk
groups are distinct.
Selection of Input Parameters
The main user-specified parameters to the iterative BMA
algorithm for survival analysis include the number of top-
ranked p genes to be included in the iterations, the nbest
strongest models to be returned by the leaps and bounds
algorithm from Furnival and Wilson [55], the desired cut-
Point for separating high- from low-risk patient samples,
and the size of the active BMA window (maxNvar). In
order to determine the best combination of these input
parameters, we performed a series of 10-fold cross valida-
tion runs on the DLBCL training data. Preliminary analy-
ses showed a cutPoint of 60 yielded better results than
either 40 or 50 (data not shown), and furthermore, a
threshold of 60% has precedence in the literature (e.g.,
[33]). As noted previously, the leaps and bounds algo-
rithm from Furnival and Wilson [55] becomes inefficient
for BMA windows larger than 30 variables. On training
sets with relatively small numbers of samples (e.g., the
breast cancer dataset used in this work), maxNvar may
need to be reduced below the 30-variable limit in order to
avoid convergence errors caused by matrix singularity and
instability in fitting the data. For this reason, we have cho-
sen a conservative default value of 25 for maxNvar. A win-
dow size of 25 provides a good balance between
approximating the maximum and avoiding convergence
errors. Our initial cross validation runs also showed that p
< 500 performed poorly, while p > 1000 did not add sig-
nificant predictive value beyond that of the first 1000
genes. Table 2 presents the results from 10 runs of 10-fold
cross validation with nbest = 10, 20, 50, and 100 for both
p = 500 and p = 1000 genes on the DLBCL dataset. The
means and standard deviations of the p-values and chi-
square statistics are calculated across all folds and all runs
for each line in the table. As shown in Table 2, the param-
eters p = 1000 and nbest = 50 produced the lowest average
p-value.
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Outline of the iterative BMA algorithm for survival analysis  on microarray data Figure 1
Outline of the iterative BMA algorithm for survival 
analysis on microarray data.
Input: training set TD with G genes and n samples 
Pre-processing step: Rank-order all G genes by applying Cox Proportional         
Hazards Regression to each individual gene. Let x1, x2, … , xG be the ordered list    
of genes, sorted in descending order of log likelihood. Let maxNvar denote 
the user-specified size of the BMA window (maximum 30). 
Parameters: nbest and p, where p is the total number of genes to be processed 
such that maxNvar < p  G. 
  1. Initially, start with the maxNvar top ranked genes (x1, x2, …, xmaxNvar),  
      and apply the traditional BMA algorithm for survival analysis (Volinsky  
      et al., 1997). Let toBeProcessed be an ordered list of genes with ranks  
      (maxNvar + 1) to p. Initially, toBeProcessed  (xmaxNvar+1, x32, …, xp).  
  2. Repeat until all p genes are processed 
  a.  Remove  all  genes  i with Pr(bi  0 | TD) < 1%. 
  b .   Adaptive threshold step: If all genes have Pr(bi  0 | TD)   1%,  
        determine the minimum Pr(bi  0 | TD), minProbne0, among the 
        maxNvar genes in the current BMA window. Remove all genes  
        with Pr(bi  0 | TD) < (minProbne0 + 1)%. 
  c.  Let  removedGenes be the set of genes removed, and suppose q 
        genes are removed. 
  d.  Replace  the  q removed genes with the q-next-up genes from  
        toBeProcessed. Update toBeProcessed  toBeProcessed –  
        q-next-up. 
    e. Apply the traditional BMA algorithm for survival analysis. 
 
Output: selected models and their posterior probabilities, selected genes and  
their corresponding posterior probabilities (Pr(bi  0 | TD)), maximum-likelihood 
estimates of the regression parameters in each model. BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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For the results shown in the rest of this paper, we adopted
the optimal input parameters (p = 1000 and nbest = 50)
determined from the 10-run/10-fold cross validation
study on the DLBCL dataset shown in Table 2 in addition
to the chosen 60% cutPoint to define risk groups. On the
DLBCL data, we used the default BMA window size (rep-
resented by the input parameter maxNvar) of 25. How-
ever, on the breast cancer data, we were unable to use the
default maxNvar value of 25. During preliminary analyses
(data not shown), we found that training sets with fewer
than 100 samples tended to result in fatal errors at higher
values of maxNvar. These errors occur because smaller
matrices lead to instability in fitting the data. These singu-
larity errors can be largely mitigated by reducing the
number of variables in the active BMA window. Since the
breast cancer training set is relatively small (61 samples vs.
160 samples in the DLBCL data), we reduced the value of
maxNvar from 25 to 15 variables in order to avoid conver-
gence errors caused by matrix singularity.
Results and discussion
Breast Cancer Data
We applied iterativeBMAsurv to the breast cancer dataset of
van't Veer et al. [27] using parameters p = 1000, nbest =
50, maxNvar = 15 and cutPoint = 60, and the algorithm
selected a total of 15 genes across 84 contending models.
Please refer to the Methods section for a detailed discus-
sion of the selection of input parameters. The number of
variables per model ranged from 5 to 10, with an average
of 8.37 genes per model. Table 3 shows the posterior
probabilities, univariate log likelihood rankings, and
descriptions of the 15 selected genes. This table shows that
Table 2: 10-run/10-fold cross validation results on the DLBCL dataset for cutPoint = 60 and maxNvar = 25.
p
(# genes)
nbest Average p-value p-value stdev Average chi-square value chi-square stdev
500 10 0.385 0.308 2.048 2.831
500 20 0.398 0.313 1.853 2.349
500 50 0.329 0.291 2.211 2.842
500 100 0.320 0.294 2.414 2.735
1000 10 0.313 0.303 2.648 3.139
1000 20 0.369 0.308 2.107 2.588
1000 50 0.307 0.303 2.958 3.251
1000 100 0.310 0.271 2.493 3.040
Table 3: Genes selected by the iterative BMA algorithm and their corresponding posterior probabilities, univariate log likelihood 
rankings, and descriptions on the breast cancer data (p = 1000, nbest = 50, maxNvar = 15, and cutPoint = 60).
Selected genes Posterior Probability
(%)
Univariate Cox ranking Gene description
NM_000767 100.0 437 cytochrome P450, subfamily IIB (phenobarbital-inducible)
NM_002019 100.0 533 fms-related tyrosine kinase 1 
(vascular endothelial growth factor/vascular permeability factor receptor)
Contig47102_RC 100.0 564 no description available
NM_013989 100.0 765 deiodinase, iodothyronine, type II (DIO2), transcript variant 1, mRNA
NM_018965 100.0 935 triggering receptor expressed on myeloid cells 2
NM_021151 99.0 956 carnitine O- octanoyltransferase
AF063936 43.9 984 putative neuronal cell adhesion molecule
NM_004911 40.6 998 protein disulfide isomerase related protein 
(calcium-binding protein, intestinal-related)
NM_014862 29.5 994 KIAA0307 gene product
Contig40146 19.0 996 wi84e 12.x1 NCI_CGAP_Kid12 Homo sapiens cDNA clone IMAGE : 2400046 
3' similar to SW: RASD_DICDI P03967 RAS- LIKE PROTEIN RASD;, mRNA 
sequence
NM_012319 17.6 993 LIV-1 protein, estrogen regulated
NM_002411 13.1 995 secretoglobin, family 2A, member 2 (SCGB2A2), mRNA
NM_003645 10.7 997 fatty-acid-Coenzyme A ligase, very long-chain 1
NM_012415 10.3 1000 RAD54 homolog B 
(S. cerevisiae), transcript variant 1, mRNA (cDNA Clone, ORF Clone)
NM_015972 9.4 999 polymerase (RNA) I polypeptide D, 16 kDa
The genes are sorted first in descending order of their posterior probabilities and second in ascending order of their univariate rankings.BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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most of the selected genes have poor univariate rankings:
the highest-ranked gene in this group is number 437 out
of 1000, and genes ranked 993 through 1000 are all
included in this set of selected predictive variables. Of the
15 genes selected by BMA, only 4 of them (27%) were
assigned a univariate ranking above 900 by the Cox Pro-
portional Hazards Model. Furthermore, the average rank-
ing of the five genes with a posterior probability of
100.0% is 646.8. Since the iterative BMA algorithm ranks
each individual gene in descending order of the log likeli-
hood resulted from fitting the Cox proportional hazards
model to each individual gene in the pre-processing step
(see Figure 1), we compared the magnitudes of the log
likelihood of the top ranked gene to the genes selected by
BMA. Our detailed analysis showed that the univariate
Cox proportional hazards model yielded similar log like-
lihoods across the top 1000 genes. Specifically, the log
likelihoods for the top univariate ranked gene
NM_012429, the 437-ranked gene NM_000767 (from
Table 3), and the 1000-ranked gene NM_012415 (from
Table 3) are -76.66, -86.53 and -88.40 respectively. Hence,
on this dataset, the poorly-ranked univariate genes pro-
duce comparable goodness-of-fit to the top ranked genes.
As a result, it is not surprising that the BMA selected genes
with poor univariate rankings achieve substantial predic-
tive power when considered in combinations.
The maximum likelihood estimate coefficients of the 15
selected genes and the posterior probabilities of the 84
selected models were used to compute the predicted risk
scores of the 234 patients in the validation dataset. We
computed the 60% cutoff point using the risk scores of the
patients in the training set, and the test samples with pre-
dicted risk scores under the cutoff point were placed in the
low-risk group. The patients whose risk scores exceeded
the cutPoint were designated as high-risk. Since the overall
prognosis for breast cancer is fairly promising relative to
other types of cancer, 179 patients (76.5%) were still alive
at the conclusion of the study. The iterative BMA algo-
rithm assigned 127 patients to the low-risk category and
107 to the high-risk category. Of the 179 patients that sur-
vived, 110 (61%) were placed in the low-risk group, while
69% (38/55) of the patients that succumbed to their dis-
ease were high-risk members. Table 4 shows the number
of patients in each group: high-risk/censored, high-risk/
uncensored, low-risk/censored, and low-risk/uncensored,
in addition to the corresponding margin totals.
Figure 2 shows the Kaplan-Meier survival analysis curve in
which the proportion of surviving patients from each risk
group is plotted against time. For the breast cancer valida-
tion samples, we found a p-value of 7.264e-05 and a chi-
square statistic of 15.741 from the log-rank test. Figure 2
and the highly significant associated p-value (< 0.0001)
show that our method assigned the validation patient
samples to relatively distinct risk groups. Furthermore,
our results compared favorably with previous work. For
example, Bair and Tibshirani [35] applied their semi-
supervised principal components method to the full data-
set of van de Vijver et al. [49]. Recall that this dataset is
comprised of 78 training samples and 295 test samples,
61 of which overlap. When testing the difference between
risk groups on the full validation set of 295 patients, Bair
& Tibshirani used only five predictor genes and reported a
p-value of 3.12e-05 from the log-rank test. They subse-
quently removed the 61 overlapping samples and applied
their method to the validation set of 234 independent
samples used in this work. With the exclusion of the over-
lapping records, their p-value increased to 0.00328. For
Table 4: The number of censored and uncensored breast cancer 
patient samples in each risk group, along with the total number 
of censored and uncensored patients and the total number of 
patients in the high- and low-risk categories.
Censored Uncensored Total
High risk 69 38 107
Low risk 110 17 127
Total 179 55
Breast cancer data, n = 234: Kaplan-Meier survival analysis  curve as a nonparametric estimator of the difference  between risk groups Figure 2
Breast cancer data, n = 234: Kaplan-Meier survival 
analysis curve as a nonparametric estimator of the 
difference between risk groups. In this analysis, p = 1000, 
nbest = 50, maxNvar = 15, and cutPoint = 60. Validation set 
risk scores were predicted using 15 selected genes across 84 
selected models. Survival time is given in years, p-value = 
7.26e-05, and chi-square = 15.741.
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comparison purposes, Bair & Tibshirani also analyzed the
difference between risk groups for both n = 234 and n =
295 as calculated through the discrete predictor method
described in van't Veer et al. [27]. They reported p-values
of 0.0105 and 0.00934 respectively.
In order to provide a more direct performance compari-
son between the iterative BMA method and these alterna-
tive procedures, we made some modifications. First, we
applied the previously selected 15 genes and 84 models to
the full van de Vijver et al. validation set of 295 samples.
Figure 3 displays the resulting Kaplan-Meier survival anal-
ysis curve (p-value = 3.382e-10, chi-square = 39.441). Sec-
ond, we predicted the risk scores for the validation set and
calculated the difference between the risk groups using the
top 5 genes with posterior probabilities of 100% from
Table 3. Figure 4 shows the Kaplan-Meier survival analysis
curve using these 5 genes for n = 234 (p-value = 9.063e-
06, chi-square = 19.699), and Figure 5 provides the same
information for n = 295 (p-value = 1.143e-10, chi-square
= 41.559). The exclusion of the bottom-ranked 10 genes
did not undermine predictive accuracy; in fact, the results
are slightly better than those obtained from using all 15
genes originally selected by the algorithm.
Furthermore, we investigated the effect of the adaptive
threshold heuristic in which the posterior probability
threshold is increased temporarily to ensure that at least
one gene is removed in each iteration. Our exploration
showed that the adaptive threshold played an important
role in the results shown in Table 3. Specifically, many of
the high univariate ranked genes were removed due to the
adaptive threshold. If we turned off the adaptive threshold
heuristic, there will only be a single iteration of bic.surv
since all the top univariate ranked genes produced poste-
rior probabilities greater than the 1% threshold. Without
the adaptive threshold, our analysis showed that using the
top 15 univariate genes produced less distinct risk groups
(p-value = 6.21e-4, chi-square = 11.712 for n = 234). We
have also explored the keepRmModels=TRUE heuristic in
which all the models discarded due to the adaptive thresh-
old were re-considered by the Occam's window method.
In this case, our analysis yielded mostly high-ranked uni-
variate genes (32 genes spanning across 217 models) that
produced slightly less distinct risk groups (p-value =
2.31e-3, chi-square = 9.283 for n = 234). Please refer to
Additional file 1 for more detailed results using this heu-
ristic.
Breast cancer data, n = 295: Kaplan-Meier survival analysis  curve calculated on the full 295-sample breast cancer valida- tion set of van de Vijver et al. [49] Figure 3
Breast cancer data, n = 295: Kaplan-Meier survival 
analysis curve calculated on the full 295-sample 
breast cancer validation set of van de Vijver et al. 
[49]. In this analysis, p = 1000, nbest = 50, maxNvar = 15, and 
cutPoint = 60. Validation set risk scores were predicted using 
15 selected genes across 84 selected models. Survival time is 
given in years; p-value = 3.38e-10 and chi-square = 39.441.
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5-gene Breast cancer data, n = 234: Kaplan-Meier survival  analysis curve as a nonparametric estimator of the difference  between risk groups Figure 4
5-gene Breast cancer data, n = 234: Kaplan-Meier 
survival analysis curve as a nonparametric estimator 
of the difference between risk groups. In this analysis, p 
= 5, nbest = 50, maxNvar = 15, and cutPoint = 60. Validation 
set risk scores were predicted using 5 top-ranked genes 
across 2 selected models. Survival time is given in years, p-
value = 9.06e-06, and chi-square = 19.699.
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Table 5 summarizes the comparison in terms of the p-val-
ues, chi-square statistics and numbers of predictor genes
across all aforementioned methodologies for the two dif-
ferent breast cancer validation sets. As shown in Table (5),
our iterative BMA algorithm produced lower p-values and
higher chi-square statistics than the other two studies
using only 5 predictor genes.
DLBCL Data
For the DLBCL data, the iterative BMA algorithm for sur-
vival analysis with the adaptive threshold heuristic using
p = 1000, nbest = 50, maxNvar = 25 and cutPoint = 60
selected a total of 25 predictive genes contained within 3
contending models. The models contained 24, 23, and 25
genes respectively. Of the 25 genes selected, 23 had a pos-
terior probability of 100.0%, which means that these 23
genes were included in all three models. Table 6 lists these
25 selected genes, along with their descriptions, posterior
probabilities, and univariate log likelihood rankings. This
table also demonstrates that genes with poor univariate
rankings may be selected by our BMA algorithm. For
example, both the highest-ranked gene (BC012161) and
the lowest-ranked gene (U70981) in the top p = 1000
genes were included in the final set of predictive variables.
In addition, several genes with rankings between 500 and
1000 were returned with calculated posterior probabilities
of 100.0% (e.g., D83492, AK025754, and NM_005347).
Our algorithm computed the predicted risk scores of the
test samples using the maximum likelihood estimate coef-
ficients of the selected genes and the posterior probabili-
ties of the selected models. The risk groups were assigned
using the 60% cutoff point of the calculated risk scores in
the training set. Of the 80 samples in the validation data-
set, 24 were assigned to the high-risk category while 56
were deemed low-risk. Only 3 patients in the high-risk
group were still alive at the final follow-up visit, while 27
low-risk patients survived to the study's conclusion. Table
7 provides a summary of the patient samples in each cat-
egory, along with the margin totals. The majority of
5-gene Breast cancer data, n = 295: Kaplan-Meier survival  analysis curve calculated on the full 295-sample breast cancer  validation set of van de Vijver et al. [49] Figure 5
5-gene Breast cancer data, n = 295: Kaplan-Meier 
survival analysis curve calculated on the full 295-sam-
ple breast cancer validation set of van de Vijver et al. 
[49]. In this analysis, p = 5, nbest = 50, maxNvar = 15, and cut-
Point = 60. Validation set risk scores were predicted using 5 
top-ranked genes across 2 selected models. Survival time is 
given in years, p-value = 1.14e-10, and chi-square = 41.559.
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Table 5: A comparison of the p-values and chi-square statistics from the log-rank test and numbers of genes selected across different 
survival analysis methods on the full breast cancer validation set of van de Vijver et al. [49] (n = 295), and the partial breast cancer 
validation set used in this work with 61 overlapping samples removed (n = 234).
heuristic # genes n = 234 n = 234 n = 295 n = 295
p-value chi-
square
p-value chi-
square
iterative BMA adaptive threshold, 
keepRmModels = FALSE
15 7.264E-05 15.714 3.382E-10 39.441
iterative BMA top 5 genes with 100% 
posterior probabilities
5 9.063E-06 19.699 1.143E-10 41.559
iterative BMA adaptive threshold, 
keepRmModels = TRUE
32 2.312E-03 9.283 9.875E-08 28.398
Bair & Tibshirani (2002) Principle 
Components
NA 5 3.280E-03 8.645* 3.120E-05 17.343*
Method of van't Veer et al. 
(2002) (as calculated by Bair & 
Tibshirani)
NA 70 1.050E-02 6.548* 9.340E-03 6.757*
The chi-square statistics marked with an asterisk (*) are computed using the p-values since the chi-square statistics are not directly available from 
Bair and Tibshirani [35]. Our iterative BMA method using the adaptive threshold produced the lowest p-value and highest chi-square statistic 
(shown in bold) using the smallest number of predictor genes.BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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patients in the DLBCL validation dataset did not survive
(50/80 = 62.5%), which explains the relatively large
number of dead patient samples assigned to the low-risk
group. Of the 30 patients who were alive at the final visit,
only 3 (10%) were placed in the high-risk category.
To assess the difference between high- and low-risk
patient categories, the p-value from the log-rank test was
calculated using the central chi-square distribution. The
two risk groups showed a significant difference in survival
probability at p-value = 0.00139 and chi-square = 10.221.
Figure 6 shows the Kaplan-Meier survival analysis curve,
where survival time is given in years. These results are
comparable with previous studies using the same division
between the training and testing sets on the DLBCL data.
Rosenwald et al. [50] identified four separate gene-expres-
sion signatures within the patient samples, and the
number of microarray features within each signature
ranged from 37 to 1333. The p-values illustrating the dif-
ference between high-, medium-, and low-risk validation
samples in each of the four signatures ranged from 0.009
to 0.11. Bair and Tibshirani [35] used a semi-supervised
principal components method to separate the validation
set of 80 DLBCL patients into high- and low-risk groups.
They used 17 genes in their analysis and reported a p-
value of 0.00124. These results are summarized in Table 8.
As with the breast cancer data, we restricted the number of
predictor variables in the DLBCL training set to include
only those genes with posterior probabilities of 100%.
Because 23 of the 25 genes originally selected by iterativeB-
MAsurv  belonged in this category, the outcome was
almost identical to the results presented in Figure 6. This
information suggests that re-running the algorithm with a
reduced set of predictor variables may be more worth-
while when relatively fewer genes are calculated to have
the maximum posterior probability.
Comparison with Other Methods
Here we compared our iterativeBMAsurv results to that
from using ridge regression which was shown to produce
Table 6: Genes selected by the iterative BMA algorithm and their corresponding posterior probabilities, univariate log likelihood 
rankings, and descriptions on the DLBCL dataset (p = 1000, nbest = 50, maxNvar = 25, and cutPoint = 60).
Selected genes Posterior Probability
(%)
Univariate Cox ranking Gene description
BC012161 100.0 1 septin 1
D42043 100.0 4 KIAA0084 protein
X53505 100.0 41 ribosomal protein S12
BF129543 100.0 49 ESTs, weakly similar to A47224 thyroxine-binding globulin precursor
D13666 100.0 73 osteoblast specific factor 2 (fasciclin I-like)
M83664 100.0 93 MHC, class II, DP beta I
AK000978 100.0 101 hypothetical protein FLJ10116
AF009615 100.0 116 a disintegrin and metallo- proteinase domain 10
AK027711 100.0 123 hypothetical protein MGC3234
LC_24015 100.0 129 no description available
K01144 100.0 140 CD74 antigen (invariant polypeptide of MHC, class II antigen associated)
U68418 100.0 181 branched chain aminotransferase 2
D88532 100.0 213 phosphoinositide-3-kinase, regulatory subunit, polypeptide 3 (p55, gamma)
NM_022551 100.0 223 ribosomal protein S18
U18259 100.0 242 MHC, class II transactivator
X64707 100.0 243 ribosomal protein L13
NM_006312 100.0 278 nuclear receptor co- repressor 2
M58297 100.0 385 zinc finger protein 42 (myeloid- specific retinoic acid-responsive)
LC_26524 100.0 473 no description available
AK022743 100.0 499 hypothetical protein FLJ12681
NM_005347 100.0 518 heat shock 70 kDa protein 5 (glucose-regulated protein 78 kDa)
D83492 100.0 632 EphB
AK025754 100.0 652 HP1-BP74
AA747694 81.7 885 ESTs, weakly similar to ALU SUBF J
U70981 9.2 1000 interleukin 13 receptor, alpha 2
The genes are sorted in descending order of their posterior probabilities and ascending order of their univariate rankings.
Table 7: The number of censored and dead DLBCL patients in 
each risk group, along with the total number of censored and 
dead patients and the total number of patients in the high- and 
low-risk categories.
Censored Died Total
High risk 3 21 24
Low risk 27 29 56
Total 30 50BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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the best overall prediction accuracy in a recent empirical
study from Bovelstad et al. [42]. Specifically, Bovelstad et
al. compared the prediction performance of seven meth-
ods that are based on the Cox proportional hazards
model, including univariate selection, forward selection,
principal components regression, supervised principal
components regression, partial least squares regression,
ridge regression and LASSO. Since Bovelstad et al.
reported results produced by randomly splitting three
microarray datasets into training and test sets, our results
are not directly comparable with theirs. Therefore, we
downloaded their software implementation written in
Matlab from their supplementary web site [64], ran their
software on the breast cancer and DLBCL datasets from
which we derived our results, and then assessed the results
using the log-rank test. On the breast cancer data, ridge
regression produced a p-value of 0.00340 using all 4919
genes. In contrast, our iterativeBMAsurv algorithm pro-
duced a much more significant p-value of 9.063e-06 using
only 5 genes. On the DLBCL data, ridge regression pro-
duced a p-value of 0.000380 using all 7399 genes. In con-
trast, our iterativeBMAsurv algorithm produced a p-value
of 0.001389 using 25 genes. Bovelstad et al. focused on
prediction accuracy instead of the number of selected
genes. In summary, ridge regression may produce good
prediction accuracy, but it is not a variable selection algo-
rithm. On the other hand, our iterativeBMAsurv algo-
rithm typically selects a small number of genes and
produces good prediction accuracy.
Conclusion
In this paper, we have proposed an extension of the itera-
tive BMA algorithm of Yeung et al. [19] for application to
survival analysis with high-dimensional microarray data.
This multivariate technique accounts for model uncer-
tainty by averaging over the posterior probabilities of the
strongest contending models (sets of potentially overlap-
ping predictor genes). We have demonstrated that our iter-
ativeBMAsurv  algorithm achieves highly significant p-
values and larger chi-square statistics from the log-rank
test on the breast cancer data when compared to alterna-
tive methods using the same number of predictor genes.
In addition, our algorithm produces similar results on the
DLBCL dataset when compared to the best method in the
literature. Table 9 provides a summary of our results. The
output of the iterative BMA algorithm for survival analysis
is particularly well suited to biological interpretation. The
posterior probability of a chosen gene represents its over-
all contribution towards the patient risk score across all
selected models. The posterior probabilities of the chosen
models indicate the relative strength of the predictor
genes from each model in patient risk assessment. The
models chosen for the breast cancer and DLBCL datasets
are relatively simple, consisting of anywhere from 5 to 25
genes. The p-values and Kaplan-Meier survival analysis
curves are used to estimate the difference between risk
groups, demonstrating the strength of the iterative BMA
algorithm as measures of high predictive accuracy.
Our results showed that genes with poor univariate rank-
ings are often selected by the iterative BMA algorithm
DLBCL data: Kaplan-Meier survival analysis curve as a non- parametric estimator of the difference between risk groups Figure 6
DLBCL data: Kaplan-Meier survival analysis curve as 
a nonparametric estimator of the difference between 
risk groups. In this analysis, p = 1000, nbest = 50, maxNvar = 
25, and cutPoint = 60. Survival time is given in years, p-value = 
0.00139, and chi-square = 10.221.
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Table 8: A comparison among three studies of the number of genes selected, the corresponding p-values and chi-square statistics in 
survival analysis on the DLBCL dataset.
Number of Genes p-value chi-square
iterativeBMA 25 0.00139 10.221
Bair & Tibshirani (2004) 17 0.00124 10.430*
Rosenwald et al. (2002) 37–1333 0.009 – 0.11 2.554 – 6.823*
The chi-square statistics marked with an asterisk (*) are computed using the p-values since the chi-square statistics are not directly available from 
Bair and Tibshirani [35].BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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using the adaptive threshold heuristic (see Tables 3 and
6). Our analysis showed that genes with dramatic differ-
ence in the univariate rankings may in fact have similar
goodness-of-fit (i.e. comparable log likelihood) when fit-
ted to the univariate Cox proportional hazards model. On
the breast cancer data, we showed that our selected set of
genes (with poor univariate rankings) resulted in patients
being assigned to more distinct risk groups than the top
univariate genes. While it is true that the genes and mod-
els selected by the iterative BMA procedure are contingent
upon the initial univariate rankings, all p top-ranked uni-
variate genes may be included in the models selected by
our iterativeBMAsurv method. Our results showed that set-
ting the parameter p to a large value (e.g., 1000) generally
yields high prediction accuracy. In addition to the param-
eter p, our algorithm requires the input of a few other user-
specified parameters. One example is nbest, which is used
by the leaps and bounds algorithm from Furnival and
Wilson [55] to isolate the nbest strongest models. Higher
values of nbest increase the computation time, but overly
restrictive values undermine predictive accuracy by failing
to return potentially contributory models. We found that
nbest = 20, 50, and 100 generally yielded good results,
with a value of 50 exhibiting the ideal tradeoff between
predictive power and computational efficiency on the
DLBCL data. For example, it takes about 1.5 hours to run
the iterative BMA algorithm with p = 1000 genes and nbest
= 50 on a machine with 2 gigabytes of RAM and a 2.0 GHz
Intel dual core processor. Reducing nbest to 20 cuts the
running time down to 40 minutes, but the p-value and
chi-square statistic representing the difference between
risk groups is slightly less favorable. On the other hand,
setting nbest to 100 significantly increases the computa-
tion time with no appreciable improvement in prediction.
Cross validation can be used to determine the optimal
input parameters for each dataset.
While the results obtained in this study are encouraging,
the iterative BMA algorithm for survival analysis presents
some limitations and areas for future development. The
mathematical calculations conducted by the BMA meth-
ods are close approximations, but they could be com-
puted with greater precision. For example, the maximum
likelihood estimate of equation (3) provides a sufficient
approximation to the predictive distribution, but the
more computationally intensive Markov Chain Monte
Carlo methods might yield the true predictive distribution
with greater accuracy [31]. The approximation of the pos-
terior model probabilities calculated in equation (6)
could also be improved [62]. Another area for future work
lies in the assessment of the performance from different
computational methods. Currently, computational meth-
ods are evaluated by comparing the separation between
different risk groups using the log-rank test (e.g. [35,50]).
In our work, we divided patients into the high and low
risk groups using cutPoint = 60% and evaluated computa-
tional methods based on the p-values and chi-square sta-
tistics computed using the log-rank test. Note that we are
only comparing the p-values over identical test sets. Com-
paring p-values across different test sets could potentially
be mis-leading, and hence, we recommend using both the
p-values and chi-square statistics when evaluating differ-
ent computational methods. Further work is required to
investigate the optimal number of risk groups and to pro-
pose statistical methods for the assessment of different
computational methods across different test sets.
The iterative BMA algorithm for survival analysis is easy to
use, computationally efficient, and highly accurate. It
Table 9: A summary of the results from the application of the iterative BMA algorithm to the DLBCL dataset, the partial non-
overlapping breast cancer dataset (n = 234), and the full overlapping breast cancer dataset (n = 295).
Number of Genes Number of Models p-value chi-square
DLBCL 25 3 1.389e-03 10.221
Breast Cancer
n = 234
(15 genes)
15 84 7.264e-05 15.714
Breast Cancer
n = 295
(15 genes)
15 84 3.382e-10 39.441
Breast Cancer
n = 234
(5 genes)
5 2 9.063e-06 19.699
Breast Cancer
n = 295
(5 genes)
5 2 1.143e-10 41.559BMC Bioinformatics 2009, 10:72 http://www.biomedcentral.com/1471-2105/10/72
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identifies a handful of predictor variables from vast
amounts of microarray data, making it a cost-effective
diagnostic tool in the clinical setting. In terms of future
work, we would like to collaborate with cancer biologists
to validate the predictor genes selected by applying the
iterativeBMAsurv  algorithm to microarray data, and to
assess the prediction accuracy of our methodology on
PCR data generated using independent patient samples.
Furthermore, we would like to extend the iterative BMA
algorithm to other types of high-throughput data such as
proteomics data produced from mass spectrometry. The
multivariate nature of BMA combined with its ability to
account for model uncertainty makes it an attractive can-
didate to extract predictive genes from any high-dimen-
sional biological data.
All analyses in this study were conducted using R statisti-
cal software http://www.r-project.org/. The Bioconductor
packages for the iterative BMA algorithms for classifica-
tion and survival analysis described in this paper are avail-
able for download from Bioconductor's website http://
www.bioconductor.org/ as the iterativeBMA and iterativeB-
MAsurv packages respectively. Please visit our supplemen-
tal website for access to the breast cancer and DLBCL
datasets, along with other helpful links and information.
Supplemental website
URL:  http://expression.washington.edu/publications/
kayee/ibmasurv/
Software
Our software implementation is publicly available as a
bioconductor package called "iterativeBMAsurv"
http:www.bioconductor.org/packages/2.3/bioc/htmitera-
tiveBMAsurv.html
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